EOLS · Evolus, Inc. · Financials
Market Cap
$523.78M
Shares
66.05M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$297.18M
+11.6%
FY2025
Net Income
-$51.64M
-2.4%
FY2025
Gross Margin
66.33%
-2.1pp
FY2025
Operating Margin
-10.99%
+1.9pp
FY2025
Diluted EPS
-$0.80
+1.2%
FY2025
Operating Cash Flow
-$42.27M
-134.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2028 (G) | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $450M – $500M | $330M – $337M | $316.49M | $297.18M | $266.27MG | $202.09M | $148.62M | $99.67M | $56.54M | $34.93M | $0 | — | |
| — | — | $105.28M | $100.07M | $83.97M | $64.51M | $58.84M | $43.53M | $18.3M | $8.01M | $0 | — | |
| — | — | $211.21M | $197.11M | $182.3M | $137.57M | $89.77M | — | — | $26.91M | $0 | — | |
| — | — | — | 66.33% | 68.46% | 68.08% | 60.41% | — | — | 77.05% | — | — | |
| — | — | $9.66M | $9.58M | $9.17M | $6.56M | $4.74M | $2.06M | $1.72M | $3.97M | $6.49M | $6.69M | |
| — | — | $43.2M | — | — | — | — | — | — | — | $29.15M | $4.82M | |
| — | — | $216.5M | $220.79M | $198.03M | $164.94M | $141.84M | $112.07M | $98.19M | $113.59M | $29.15M | — | |
| — | — | $7.27M | $6.27M | $4.1M | $4.07M | $3.35M | $5.31M | $3.64M | $3.85M | $0 | — | |
| — | — | $8.89M | $7.51M | $5.3M | $5.13M | $3.72M | $5.62M | $7.03M | $4.13M | $9000 | $218K | |
| — | — | — | $1.44M | $0 | $0 | — | $0 | $2.96M | $0 | — | — | |
| — | — | $98.34M | — | — | — | — | — | — | $125.86M | $46.14M | $11.73M | |
| — | — | $229.88M | $229.77M | $216.72M | $186.8M | $155.1M | $144.08M | $209.61M | $133.87M | — | — | |
| — | — | -$18.67M | -$32.66M | -$34.41M | -$49.23M | -$65.33M | -$44.41M | -$153.07M | -$98.95M | -$46.14M | -$11.73M | |
| — | — | — | -10.99% | -12.92% | -24.36% | -43.96% | -44.55% | -270.73% | -283.31% | — | — | |
| — | — | -$9.79M | -$25.16M | -$29.11M | -$44.1M | -$61.61M | -$38.78M | -$146.04M | -$94.82M | -$46.13M | -$11.51M | |
| — | — | $16.22M | $19.69M | $18.74M | $13.83M | $9.1M | $1.4M | — | — | $863K | $5000 | |
| — | — | — | — | — | — | — | — | — | — | $203K | $0 | |
| — | — | -$112K | -$539K | $127K | $696K | -$9000 | $0 | -$10.5M | -$7.95M | -$863K | — | |
| — | — | -$33.68M | -$50.96M | -$49.76M | -$61.51M | -$74.32M | -$46.77M | -$162.94M | -$105.06M | -$46.8M | -$11.73M | |
| — | — | $654K | $677K | $664K | $176K | $95K | $42K | $77K | -$15.03M | $65K | -$7.25M | |
| — | — | -$34.33M | -$51.64M | -$50.42M | -$61.69M | -$74.41M | -$46.81M | -$163.01M | -$90.03M | -$46.87M | -$4.48M | |
| — | — | — | -17.38% | -18.94% | -30.52% | -50.07% | -46.96% | -288.31% | -257.79% | — | — | |
| — | — | -$34.26M | -$50.89M | -$50.9M | -$61.78M | -$74.75M | -$46.81M | -$163.02M | -$90.03M | -$46.87M | -$4.48M | |
| USD/shares | — | — | -$0.51 | -$0.80 | -$0.81 | -$1.08 | -$1.33 | -$0.94 | -$4.83 | — | — | — |
| USD/shares | — | — | -$0.51 | -$0.80 | -$0.81 | -$1.08 | -$1.33 | -$0.94 | -$4.83 | — | — | — |
| shares | — | — | — | 64.47M | 62.02M | 56.92M | 56.07M | 49.77M | 33.74M | 28.24M | 24.4M | 16.53M |
| shares | — | — | — | 64.47M | 62.02M | 56.92M | 56.07M | 49.77M | 33.74M | 28.24M | 24.4M | 16.53M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
2.01×
Peer median 1.84×
EV/EBIT
—
Peer median 14.31×
P/E (TTM)
—
Peer median 13.58×
Peer medians compare against the 49 similar-size Drug Manufacturers - Specialty & Generic companies (of 100 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $297,176,000 | $266,274,000 | $202,085,000 | $148,616,000 |
By Geography (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| United States | $253,159,000 | $195,424,000 | $146,150,000 | — | — | — |
| Non Us | $13,115,000 | $6,661,000 | $2,466,000 | — | — | — |
| Canada | — | — | — | $702,000 | $738,000 | $688,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Product | $294,956,000 | $264,306,000 | $199,721,000 | $146,592,000 | $98,971,000 | $55,802,000 | $34,237,000 |
| Service | $2,220,000 | $1,968,000 | $2,364,000 | $2,024,000 | $702,000 | $738,000 | — |
Key facts
CIK
1570562
CUSIP
30052C107
13F (30d)
13 filings
13 filers
Visit website
Investor relations